Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA panCAR is an investigational chimeric antigen receptor (CAR) cell therapy being developed by **Xianbo Biotechnology** (also known as **Simnova Bio**) in collaboration with **Orna Therapeutics**. The therapy utilizes Xianbo's proprietary **panCAR** platform, which is designed to enhance the precision and efficacy of CAR-based treatments. By targeting the **B-cell maturation antigen (BCMA)**, a protein highly expressed on the surface of malignant plasma cells, the therapy aims to treat hematologic malignancies such as multiple myeloma. The partnership with Orna Therapeutics likely leverages Orna's circular RNA (oRNA) technology, which may be used to facilitate the expression of the CAR construct, potentially through *in vivo* delivery or optimized *ex vivo* engineering.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BCMA panCAR.